AC
APTO

Armistice Capital’s Aptose Biosciences, Inc. APTO Stock Holding History

Armistice Capital’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-62,933
Closed -$776K – 320
2024
Q3 		$776K Buy
62,933
+5,833
+10% +$88.8K 0.01% 178
2024
Q2 		$1.3M Buy
+57,100
New +$1.94M 0.02% 157

Other funds holding APTO

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AC
Annandale Capital Dallas, Texas $709M AUM 11.03% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital's APTO Position: Q4 2024 in Review

Armistice Capital sold out of Aptose Biosciences, Inc. (APTO) in Q4 2024, closing a stake of 62,933 shares — an estimated $776K sold.

Armistice Capital first reported a position in APTO in Q2 2024 and held it in 2 quarters. The position peaked at $1.3M in Q2 2024. 22 funds tracked by Wall St. Rank hold APTO as of Q4 2024.

  • Armistice Capital reported no remaining Aptose Biosciences, Inc. position as of Q4 2024 after selling out during the quarter.
  • Armistice Capital sold 62,933 Aptose Biosciences, Inc. shares in Q4 2024, an estimated $776K.
  • Armistice Capital first reported a position in Aptose Biosciences, Inc. in Q2 2024 and held it in 2 quarters.
  • Armistice Capital's Aptose Biosciences, Inc. position peaked at $1.3M in Q2 2024.
  • 22 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q4 2024.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.